顺铂联合吉西他滨或多西他赛治疗中老年晚期非小细胞肺癌的疗效观察

Efficacy of cisplatin combined with gemcitabine and docetaxel in elderly patients with advanced nonsmall cell lung cancer

目的探讨吉西他滨与多西他赛联合顺铂治疗中老年晚期非小细胞肺癌的临床疗效。方法选取2018年3月至2020年3月间陕西省安康市中心医院收治的90例中老年晚期非小细胞肺癌患者为研究对象。根据治疗方法不同进行分组,其中,采用多西他赛联合顺铂治疗的45例患者纳入对照组,采用吉西他滨联合顺铂治疗的45例患者纳入观察组。治疗结束后,比较两组患者不良反应发生率和疾病控制率。结果观察组患者贫血、腹泻、血小板减少和白细胞减少的发生率低于对照组患者,差异均有统计学意义(均P<0.05),两组患者呕吐和乏力的发生率比较,差异无统计学意义(P>0.05)。观察组疾病控制率为75.6%,对照组疾病控制率为66.7%,两组比较,差异无统计学意义(P>0.05)。结论采用吉西他滨与多西他赛分别联合顺铂对中老年晚期非小细胞肺癌患者的疗效均较好,但吉西他滨联合顺铂治疗能更有效减少患者的不良反应,适宜在临床推广应用。

Objective To observe and compare the efficacy of cisplatin combined with gemcitabine or docetaxel in the treatment of advanced non-small cell lung cancer in the elderly patients.Methods Ninety middle-aged and elderly patients with advanced non-small cell lung cancer admitted to Ankang Central Hospital from March 2018 to March 2020 were selected as the research subjects.They were divided into an observation group and a control group based on the treatment they received with 45 patients in each group.The observation group was given gemcitabine combined with cisplatin and the control group was given docetaxel combined with cisplatin.After treatment,the incidence of adverse reactions and disease control rate were compared between the two groups.Results The incidence of anemia,diarrhea,thrombocytopenia,and leukopenia were lower in the observation group than in the control group(all P<0.05).There was no significant difference in the incidence of vomiting and fatigue between the two groups(P>0.05).The disease control rate was 75.6%in the observation group which was lower than 66.7%of the control group(P>0.05).Conclusion Cisplatin combined with gemcitabine and docetaxel are effective in middle-aged and elderly patients with advanced non-small cell lung cancer,and gemcitabine combined with cisplatin can more effectively reduce the incidence of adverse reactions,and it is worthy of clinical application.